抗凝房颤患者中轻微出血的预后意义
基于ORBIT-AF前瞻性门诊注册研究,纳入6771例口服抗凝的房颤患者,评估轻微出血(无需医疗关注的出血)与后续大出血及卒中/系统性栓塞的关系。结果显示轻微出血发生率为14.8例/100人年,但校正评分后并未显著增加6个月内大出血或卒中/系统性栓塞风险,提示不应因此改变抗凝策略。
要点
- 轻微出血在抗凝房颤患者中常见,发生率14.8例/100人年。
- 轻微出血后6个月内大出血风险未显著升高(OR 1.04;95%CI 0.68-1.60;P=0.86)。
- 轻微出血后6个月内卒中/系统性栓塞风险未显著升高(OR 1.24;95%CI 0.53-2.91;P=0.62)。
核心结论
- 轻微出血在口服抗凝的房颤患者中常见,但未与后续6个月内大出血或卒中/系统性栓塞风险显著相关,不应因此改变抗凝治疗策略。
研究设计与样本
- ORBIT-AF前瞻性门诊注册研究,纳入172个中心6771例≥18岁房颤患者,分析单位為患者访视(约每6个月一次,中位随访1.5年)。
主要发现
- 轻微出血后超过96.4%的患者继续口服抗凝治疗。
- 随访期间287例(4.3%)发生大出血,64例(0.96%)发生卒中/系统性栓塞。
- 校正ATRIA出血评分后,轻微出血与6个月内大出血风险无显著关联(OR 1.04;95%CI 0.68-1.60;P=0.86)。
- 校正CHA2DS2-VASc评分后,轻微出血与6个月内卒中/系统性栓塞风险无显著关联(OR 1.24;95%CI 0.53-2.91;P=0.62)。
临床怎么用
- 对于口服抗凝的房颤患者,发生无需医疗关注的轻微出血时,不应据此停用或更改抗凝治疗。
局限性
- 轻微出血通过病历记录确认,可能存在漏报或错分。
- 抗凝治疗满意度变化仅在部分患者中描述性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bleeding is commonly cited as a reason for stopping oral anticoagulants (OACs). Whether minor bleeding events (nuisance bleeding, NB) in patients with atrial fibrillation on OACs are associated with OAC discontinuation, major bleeding, and stroke/systemic embolism (SSE) is unknown. METHODS: Within the ORBIT-AF prospective, outpatient registry (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), we identified 6771 patients ≥18 years of age at 172 sites with atrial fibrillation and eligible follow-up visits. NB was ascertained from the medical record and was defined as minor bleeding that did not require medical attention (eg, bruising, hemorrhoidal bleeding). We used multivariable pooled logistic regression modeling to evaluate the associations between NB and major bleeding and SSE in the 180 days after documentation of NB. Our unit of analysis was the patient visit, occurring at ≈6-month intervals for a median of 1.5 years following enrollment. Changes in anticoagulation treatment satisfaction after NB were examined descriptively in a subset of patients. RESULTS: The median age of the overall population was 75.0 (interquartile range, 67.0-81.0); 90.0% were white and 42.5% were female. Among 6771 patients (18 560 visits), n=1357 (20.0%) had documented NB, for an incidence rate of 14.8 events per 100 person-years. Over 96.4% of patients remained on OAC therapy after the NB event. Overall, 287 (4.3%) patients experienced major bleeding and 64 (0.96%) had a SSE event during follow-up. NB was not associated with a significant increased risk of major bleeding over 6 months in models adjusting for the ATRIA bleeding score (Anticoagulation and Risk Factors in Atrial Fibrillation) (odds ratio, 1.04; 95% confidence interval, 0.68-1.60; P=0.86). NB was also not associated with increased SSE risk over 6 months in models adjusting for the CHA2DS2-VASc risk score (odds ratio, 1.24; 95% confidence interval, 0.53-2.91; P=0.62). CONCLUSIONS: NB is common among patients with atrial fibrillation on OACs. However, NB was not associated with a higher risk of major bleeding or SSE over the next 6 months, suggesting its occurrence should not lead to changes in anticoagulation treatment strategies in OAC-treated patients. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01165710.
引用
- O'Brien EC, Holmes DN, Thomas LE, et al. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation. 2018. PMID: 29678813. doi:10.1161/CIRCULATIONAHA.117.031354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。